Neurogene Inc. short interest in 2020
In 2020, Neurogene Inc.'s disclosed short interest ran from 4.27% of shares outstanding on 13 Mar 2020 to 7.15% on 31 Dec 2020, a change of +2.88 percentage points. The year's high was 8.75% on 30 Jun 2020 and its low 4.13% on 31 Mar 2020, averaging 6.13% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.24 days on 15 Oct 2020. Full history: Neurogene Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2020 in figures
- Start of year
- 4.27% (13 Mar 2020)
- End of year
- 7.15% (31 Dec 2020)
- Change
- +2.88 pp
- High
- 8.75% (30 Jun 2020)
- Low
- 4.13% (31 Mar 2020)
- Average
- 6.13%
- Highest days to cover
- 16.24 (15 Oct 2020)
- SEC filings marked
- 8
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Mar 2020 | 4.27% | 6.64 | 10-K filed, results (8-K) |
| 31 Mar 2020 | 4.13% | 4.65 | |
| 15 Apr 2020 | 4.24% | 5.81 | |
| 30 Apr 2020 | 5.22% | 8.54 | |
| 15 May 2020 | 5.53% | 11.53 | 10-Q filed, results (8-K) |
| 29 May 2020 | 5.66% | 14.65 | |
| 15 Jun 2020 | 6.06% | 8.22 | |
| 30 Jun 2020 | 8.75% | 3.76 | |
| 15 Jul 2020 | 7.98% | 4.20 | |
| 31 Jul 2020 | 8.30% | 12.21 | |
| 14 Aug 2020 | 7.74% | 13.78 | 10-Q filed, results (8-K) |
| 31 Aug 2020 | 6.55% | 14.58 | |
| 15 Sep 2020 | 6.38% | 15.31 | |
| 30 Sep 2020 | 6.13% | 12.54 | |
| 15 Oct 2020 | 6.02% | 16.24 | |
| 30 Oct 2020 | 6.10% | 15.98 | |
| 13 Nov 2020 | 5.74% | 11.72 | 10-Q filed, results (8-K) |
| 30 Nov 2020 | 5.35% | 14.30 | |
| 15 Dec 2020 | 5.23% | 13.80 | |
| 31 Dec 2020 | 7.15% | 2.65 |
See also: Neurogene Inc.'s full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.